Novo Nordisk is a global pharmaceutical leader specializing in diabetes, obesity, and metabolic diseases. The company is best known for its GLP-1 therapies such as Ozempic and Wegovy, which have reshaped the global treatment landscape for diabetes and weight management.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
$NVO (1M)
Sector: Healthcare
Industry: Pharmaceuticals (Diabetes & Obesity Care)
Novo Nordisk is a global pharmaceutical leader specializing in diabetes, obesity, and metabolic diseases. The company is best known for its GLP-1 therapies such as Ozempic and Wegovy, which have reshaped the global treatment landscape for diabetes and weight management.